If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
207
results.
Updated on
14/10/2025 [06:50:00]
Results 125 to 150 of 207
Absstract of: US2025302971A1
Disclosed herein is a delivery vehicle based on DNA-inspired Janus based nanotubes (JBNTs) for anti-viral treatment. The nanoparticles (NPs) are based the JBNTs conjugated with targeting moieties such as small molecules, aptamers, and peptides.
Absstract of: AU2024249750A1
Peptides which are capable of penetrating mucosal membranes or cell membranes are provided. In some aspects, functionalized peptide conjugates are provided. Compositions of peptide conjugates are disclosed, and methods of using such compositions are provided.
Absstract of: AU2024229078A1
The present invention relates to nanocomplexes (NCs) comprising a polysaccharide nanoparticle (NP) and a hormone selected from insulin, glucagon, or glucagon-like protein-1, and uses thereof for reducing the blood glucose level, in particular, for the treatment of diabetes.
Absstract of: AU2024250699A1
The present disclosure provides novel compounds, methods, and cell targeting mRNA vaccine formulations for targeted delivery, such as delivery to dendritic cells. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features specific for dendritic cells and a lipid tail for incorporated into the bilayer membrane of the formed lipid nanoparticle.
Absstract of: WO2025200517A1
The present invention provides a lipid material for nucleic acid delivery, wherein the lipid material comprises a compound having structure I. The present invention also provides use of the lipid material for nucleic acid delivery in the preparation of a therapeutic drug for one or more selected from an infectious disease, a tumor disease, a congenital hereditary disease, and an immune disease. By means of the lipid material provided in the present invention and adopting a nucleic acid drug carrier strategy with high efficiency and low toxicity, a novel ionizable lipid and an auxiliary lipid material are mixed to encapsulate nucleic acid drugs, so that efficient and safe delivery of the nucleic acid drugs in vivo is achieved, and the druggability of the nucleic acid drugs is improved.
Absstract of: WO2025200113A1
Provided is a superoxide dismutase-based nanoscale transdermal delivery system, which is a capsule composite structure consisting of a small molecule active ingredient, superoxide dismutase, and a polymer coating. The small molecule active ingredient is loaded in the superoxide dismutase, and the surface of the superoxide dismutase is coated with the polymer coating. The superoxide dismutase-based active ingredient transdermal delivery system has a diameter of 20-100 nm, and the polymer coating has a thickness of 7.5-52.5 nm. In the delivery system, the polymer coating protects the superoxide dismutase and the small molecule functional substance having an antioxidant effect, and the capsule composite structure is in the form of nanogel. The nanogel not only promotes the penetration depth of the delivery system, but also mitigates the stimulation of the delivery system to the skin. The delivery system features biofriendly starting materials, simple preparation method, and high yield, and thus can be produced in large scale industrially.
Absstract of: WO2025207519A1
Embodiments of the present disclosure pertain to an active agent carrier that includes a disc-shaped membrane with a plurality of self-assembled amphiphilic block copolymers encased by membrane stabilizing agents, where the amphiphilic block copolymers include hydrophilic blocks and hydrophobic blocks, and where at least one active agent is associated with the disc-shaped membrane. Tunable numbers of targeting agents may also be associated with the disc-shaped membrane. Additional embodiments pertain to methods of delivering one or more active agents to a subject by administering to the subject an active agent carrier of the present disclosure. Further embodiments pertain to methods of making an active agent carrier of the present disclosure.
Absstract of: WO2025200270A1
A cationic lipid compound, a preparation method therefor, a composition comprising same, and a use thereof, relating to the technical field of biomedicine. The cationic lipid compound has relatively high transfection efficiency and relatively low cytotoxicity by introducing at least one protonatable polar headgroup containing a secondary or tertiary amine and at least two hydrophobic tails containing a specified number of carbons, and connecting the polar headgroup and the hydrophobic tails by means of a specific linker chain.
Absstract of: WO2025207378A1
Surface modification of nanoparticles (NPs) via the layer-by-layer (LbL) technique is a approach to generate targeted drug delivery vehicles. A simple and scalable synthesis method for LbL-NPs that can be adapted for clinical translation is of great interest. Presented herein is a robust and scalable method of polymer deposition onto nanoparticles.
Absstract of: WO2025207828A1
This disclosure is directed to payload bioactive agents (PBAs) that include modified exatecans. This disclosure is also directed to bioactive compositions and pharmaceutical compositions for treating cancer. The pharmaceutical compositions comprise a polymer, a targeting bioactive agent (TBA), a PBA comprising a modified exatecan that is covalently linked to the TBA directly or indirectly, a linker that can comprise a cleavable linker, and a pharmaceutical suitable carrier. The pharmaceutical compositions can be antibody-drug conjugates (ADCs) for treating cancers, with the potential for treating tumors having negative or low (AgLow) tumor antigens.
Absstract of: WO2025206286A1
The present invention addresses the problem of providing a composition for freeze-drying cells with which it is possible to suppress a decrease in survival rate or a decrease in particle size when the cells are reconstituted after freeze-drying. The composition for freeze-drying cells contains (a) a hydrophobic substance such as (a-1), (a-2), etc., and (b) nanoparticles formed from monolayers or bilayers of amphiphilic molecules, where: (a-1) is one or more hydrophobic amino acids selected from the group consisting of phenylalanine, leucine, glycine, valine, isoleucine, tryptophan, and alanine; and (a-2) is a dipeptide configured from one or two hydrophobic amino acids selected from the group consisting of phenylalanine, leucine, glycine, valine, isoleucine, tryptophan, and alanine. The composition is characterized by being used added to the cells.
Absstract of: WO2025200185A1
An astragaloside nanoformulation for the treatment of hepatitis B and a preparation method therefor. The astragaloside nanoformulation for the treatment of hepatitis B comprises astragaloside and an auxiliary material. The auxiliary material comprises at least one of a polyoxyethylene-polyoxypropylene ether triblock copolymer, phospholipid, albumin, and casein. The compounding of these auxiliary materials and astragaloside can result in an astragaloside nanoformulation with good water solubility and high bioavailability, which exhibits higher safety and efficacy for the treatment of hepatitis B.
Absstract of: WO2025207807A1
The disclosure provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, and nucleic acid molecules in the nucleic acid layers comprise a sequence of a nucleic acid molecule expressed by a circulating tumor cell (CTC). The disclosure further provides a method of treating cancer in a subject need thereof, the method comprising administering to the subject the nanoparticle described herein, optionally wherein two or more administrations of the nanoparticle are provided, wherein each administration comprises a nanoparticle comprising RNA comprising a sequence of RNA expressed in a CTC isolated from the subject at different points in time.
Absstract of: WO2025206461A1
The present invention relates to a novel lipid derivative compound comprising an oligo-gamma-glutamic acid, a lipid nanoparticle composition comprising the same, and the like. According to the present invention, the compound can form lipid nanoparticles by replacing PEGylated lipids, and thus can prevent side effects such as anaphylaxis and has excellent in vivo stability.
Absstract of: WO2025199580A1
The present invention relates to formulations, devices and methods for coating surfaces of microprojections on microprojection arrays with nucleic acids. The present invention also relates to formulations and methods for coating surfaces of microprojections with nucleic acids where the nucleic acids are associated with lipid nanoparticles (LNP), in particular where the nucleic acid is mRNA.
Absstract of: WO2025207986A1
The present invention provides delivery-enhancing polymers capable of being encapsulated in nanoparticles to enhance release of payload from the nanoparticle wherein the delivery-enhancing polymer comprises a polyamine comprising tertiary amine. The delivery-enhancing polymer may comprise methylated polyethylenimine (mPEI), branched PEI (bPEI), PAMAM dendrimer and/or histidine polymer.
Absstract of: WO2025206323A1
The present disclosure provides a novel modality for a new target disease (e.g. pancreatic cancer). The present disclosure applies a mRNA CAR-T vaccine to CAR-T for a new target disease (e.g., pancreatic cancer). In the present disclosure, it has been revealed, by in vitro and in vivo experiments, that a mRNA CAR-T vaccine that targets FAP as an antigen can achieve a potent anti-tumor effect in in vivo editing. As for a mechanism for inhibiting the effect of a mRNA CAR-T vaccine, the pathways involving regulatory T cells and the like have also been revealed. As for a synergistic effect with an immune checkpoint agonist, a "condition" for achieving a potent anti-tumor effect in vivo has also been revealed through much trial and error.
Absstract of: WO2025207803A1
Described are compounds, compositions, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a nucleic acid).
Absstract of: WO2025202984A1
The present invention concerns h-ferritin complexes loaded with anti-tumoral drugs for the treatment of cancer through Boron Neutron Capture Therapy.
Absstract of: WO2025203087A1
The present disclosure discloses a recombinant construct including a vector and a recombinant nucleic acid molecule (1). The vector including at least one promoter region (13). The recombinant nucleic acid molecule (1) is encoded at least by SEQ ID No. 1. The recombinant nucleic acid molecule (1) is disposed downstream of the at least one promoter region (13) to enable transcription of the recombinant nucleic acid molecule (1) by the promoter region (13) to a plurality of messenger ribonucleic acid (mRNA) molecules encoded by SEQ ID No. 9.
Absstract of: WO2025202360A1
The present invention relates to aqueous RNA compositions that are suitable for storage, comprising Tris, a saccharide, and phosphate anions. The present invention also relates to methods of producing such aqueous RNA compositions, as well as their use in therapy and prevention of infectious diseases.
Absstract of: US2025302767A1
Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and/or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and/or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and/or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and/or cancers; and methods for inhibiting the growth, proliferation, and/or metastasis of a tumor and/or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.
Absstract of: CN120239748A
The present invention encompasses systems, kits, and compositions comprising two RNA molecules wherein a first RNA molecule comprises an open reading frame encoding a functional RNA dependent RNA polymerase (replicase), and wherein a second RNA molecule is a replicable RNA molecule comprising at least one miRNA sequence that, when present in a cell, is capable of being cleaved from the second replicable RNA, and wherein the second RNA molecule is a replicable RNA molecule that comprises at least one miRNA sequence that, when present in the cell, is capable of being cleaved from the second replicable RNA. The first RNA molecule is capable of replication and is capable of modulating gene expression in a cell, and the replicable RNA molecule is capable of trans-replication by a replicase encoded by the first RNA molecule. The invention also encompasses methods of treating or preventing cancer or infections or other diseases and disorders with such systems and compositions, and the use of such systems and compositions in such methods of treatment and prevention.
Absstract of: WO2024054855A1
The present disclosure relates to a combination therapy comprising an anti-VEGF antibody, a nanoparticle formulated plasmid comprising an IL-12 coding nucleic acid, and, optionally, at least one adjunctive chemotherapeutic drug, and methods of treatment using such combination therapies and/or compositions.
Nº publicación: JP2025532576A 01/10/2025
Applicant:
カンザス、ステート、ユニバーシティ、リサーチ、ファウンデーション
Absstract of: AU2023342067A1
Aqueous partitioning peptide capsules for delivery of active agents. The capsules comprise a membrane having an exterior surface and defining a liquid-receiving interior space configured to encapsulate water-soluble active agents therein. The capsule membrane consists of a plurality of linear peptides, each peptide comprising a hydrophobic core of between 4 and 12 hydrophobic amino acids flanked by N- and C-terminal hydrophilic segments each comprising between 3 to 4 hydrophilic amino acids. Methods of making peptide capsules and methods of using the peptide capsules to deliver active agents encapsulated therein or attached thereto to a variety of organisms is described.
BOPI
Electronic site
